Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

85
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
85
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

441
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
441
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Perspective on Epicardial Adipose tissue.

European journal of internal medicine·2025
Same author

Clinical correlates of perivascular adipose tissue in coronary artery disease and obesity.

Frontiers in physiology·2025
Same author

Ruptured Sinus of Valsalva Aneurysm: Silent and Rare Cause of Heart Failure in Young Adults.

JACC. Case reports·2025
Same author

Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?

Annals of internal medicine·2025
Same author

Editorial commentary: Epicardial Adipose Tissue and Heart Failure.

Trends in cardiovascular medicine·2025
Same author

Therapeutic appraisal in protracted heart failure.

The American journal of the medical sciences·2025

相关实验视频

Updated: Jul 13, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

813

患者为中心的心力衰竭治疗疗法

Rohan Samson1, Pierre V Ennezat2, Thierry H Le Jemtel3

  • 1Advanced Heart Failure Therapies Program, University of Louisville Health-Jewish Hospital, Ky.

The American journal of medicine
|October 14, 2023
PubMed
概括

启动心力衰竭的四重疗法,减少喷射分数可以简化. 一个新的序列优先考虑安全的脱血和快速定位,确保患者更快地获得最佳的心力衰竭治疗剂量.

关键词:
在指导方针指导的医疗治疗中.心力衰竭与减少的喷射分数心力衰竭.这是四重疗法.定位 定位 定位 定位 定位

更多相关视频

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.9K

相关实验视频

Last Updated: Jul 13, 2025

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
03:47

Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients

Published on: July 12, 2024

813
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

6.9K

科学领域:

  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.
  • 内部医学 内部医学

背景情况:

  • 减少喷射分数 (HFrEF) 的心力衰竭需要复杂的药物治疗方案.
  • 四重疗法 (血管激素受体-neprilysin抑制剂,β-上腺素受体阻断剂,矿物质皮质类受体对抗剂,SGLT2抑制剂) 改善了结果,但难以定位.
  • 延迟四倍疗法的定位可能会阻碍HFrEF患者的早期益处.

研究的目的:

  • 建议一个优化的序列,以启动入院的HFrEF患者的四重治疗.
  • 促进指南导向医疗疗的快速实施和升级.
  • 通过及时的药物优化,改善患者的治疗结果,减少再入院.

主要方法:

  • 一个新的治疗序列,从SGLT2抑制剂和矿物质皮质类受体对手开始,以确保安全的脱血.
  • 根据患者的脱血状态,逐步引入血管激素受体-neprilysin抑制剂或β-上腺素受体抑制剂.
  • 门诊定位以完成四倍治疗,优化药物剂量用于HFrEF管理.

主要成果:

  • 拟议的序列允许安全的脱和最小的初始定位.
  • 有助于快速启动关键的HFrEF药物.
  • 能够快速达到四倍治疗的目标剂量,提高治疗效率.

结论:

  • 对于HFrEF患者来说,一个结构化,顺序的四重疗法启动方法是可行的和有益的.
  • 这一战略解决了心力衰竭护理中及时药物定位的挑战.
  • 优化四重疗法启动可以提高临床结果,减少医疗保健利用率.